Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial - Oligonucleotide Therapeutics Society

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

OTS

Antisense/RNase H,Clinical Development

July 5, 2020

SHARE

Post Views: 360

Loomba R, Morgan E, Watts L, Xia S, Hannan LA, Geary RS, Baker BF, Bhanot S.

Lancet Gastroenterol Hepatol. 2020 Jun 15:S2468-1253(20)30186-2.

Related articles

Subscribe to our Newsletter

Oligonucleotide Therapeutics Society

Oligonucleotide Therapeutics Society

c/o Event Innovations, Inc.
4377 Newport Avenue
San Diego, CA 92107, USA

(619) 795-9458
info@oligotherapeutics.org

Terms & Conditions

Resources

Stay Connected

Search

Subscribe in a reader

© Copyright 2012 – 2023 | Oligotherapeutics.org | All Rights Reserved | Finfrock Marketing

Username/Email Address:
Password:
Forgot Password | Sign Up

Save Password

First Name *
Last Name *
Username *
Email *
Password *
Confirm Password *
Phone:
Organization Name
Select Sectors

By clicking checkbox, you agree to our Terms and Conditions and Privacy Policy

Already have an account? Login

This website uses cookies and third party services. Ok